BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 13.3//EN BEGIN:VTIMEZONE TZID:UTC BEGIN:STANDARD DTSTART;VALUE=DATE:20230101 TZNAME:UTC TZOFFSETFROM:+0000 TZOFFSETTO:+0000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:Under EMA Policy 70 Publication of Clinical Data\, clinical ove rviews and study reports submitted as part of a Marketing Authorisation Ap plication are published and made publically available. \; Before docum ents are published\, sponsors need to anonymise the documents aligned to d ata privacy requirements. \; \nThe intent of this webinar is to descri be what is involved in anonymising clinical data\, and present the differe nt methods and approaches available for anonymisation including an introdu ction to residual risk assessment. \; Examples from the PhUSE Data De- Identification Standard will also be discussed. \nJean-Marc Ferran (Qualia nce / PhUSE) will present &lsquo\;Anonymising Clinical Data &ndash\; key p rinciples\, methods and considerations&rsquo\;. \; Chrissie Fletcher w ill facilitate a Q&\;A session.\nFor details please contact Chrissie Fl etcher fletcher@amgen.com\nRegistration is now closed.\n\nPlease click her e \;to view the flyer.\n\nPlease click here \;to view the presenta tion slides.\n\nTo access the recording\, please visit the Video-on-Demand Library. DTEND:20171117T150000Z DTSTAMP:20240329T155251Z DTSTART:20171117T140000Z LOCATION: SEQUENCE:0 SUMMARY:EFSPI/PSI Webinar: Anonymising Clinical Data UID:RFCALITEM638473243716474073 X-ALT-DESC;FMTTYPE=text/html:
Under EMA Policy 70 Publication of Clin ical Data\, clinical overviews and study reports submitted as part of a Marketing Authorisation Application are published and made publically a vailable. \; Before documents are published\, sponsors need to anonymi se the documents aligned to data privacy requirements. \;
\nThe intent of this webinar is to describe what is involved in anonymising cli nical data\, and present the different methods and approaches available fo r anonymisation including an introduction to residual risk assessment.&nbs p\; Examples from the PhUSE Data De-Identification Standard will also be d iscussed.
\nJean-Marc Ferran (Qualiance / PhUSE) will present &lsqu o\;Anonymising Clinical Data &ndash\; key principles\, methods and conside rations&rsquo\;. \; Chrissie Fletcher will facilitate a Q&\;A sessi on.
\nFor details please contact Chrissie Fletcher fletcher@amgen.com
\nRegistration is now closed.